GE HealthCare to showcase comprehensive cardiology portfolio at ACC.26, including its latest AI-enabled imaging technologies, advanced software solutions, and key collaborations Mar 25, 2026 9:00 AM Eastern Daylight Time According to the American Heart Association, cardiovascular disease remains the leading cause of death in the United States, with one person dying every 34 seconds and more than 900,000 lives lost each year. As patient volumes rise and nearly half of U.S. adults live with some form of cardi ...

Key Takeaways GEHC entered 2026 with a $21.8B backlog and strong enterprise deal momentum supporting growth visibility.GEHC's Pharmaceutical Diagnostics grew 12.7%, driven by contrast media demand and PET imaging adoption.GEHC faces tariff impacts, margin pressure from investments, and uneven segment and regional performance.GE HealthCare Technologies, Inc. (GEHC) is well-poised for growth in the coming quarters, courtesy of its continued focus on innovations. The optimism, led by strong fourth-quarter 2025 ...

Key Takeaways GEHC secured FDA 510(k) clearance for Photonova Spectra, a photon-counting CT system.Photonova uses Deep Silicon detectors for higher resolution and better tissue differentiation.GEHC plans a U.S. rollout as the system boosts workflow, speed and advanced imaging capabilities.GE HealthCare Technologies Inc. (GEHC) recently received FDA 510(k) clearance for its Photonova Spectra, an advanced photon-counting computed tomography (PCCT) system designed to redefine diagnostic precision, workflow eff ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Dive Brief: GE HealthCare has received 510(k) clearance for its spectral photon-counting CT technology, the company said Monday. The Food and Drug Administration clearance positions GE HealthCare to compete with Siemens Healthineers’ Naeotom Alpha, the first photon-counting CT machine to reach the U.S. market. Citi Research analysts said in a note to investors th ...

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Photonovaâ"¢ Spectra,i an innovative photoncounting computed tomography (PCCT) solution powered by the company's novel Deep Silicon detector technology and offered as a flexible platform with multiple configurations to meet diverse clinical needs. With wide coverage and the combination of ultra-high definition (UHD) spatial and spectral imaging, Photonova Spec. ...

GE HealthCare Technologies Inc. (NASDAQ:GEHC) is one of the Most Undervalued Stocks to Buy According to Analysts. On March 12, Citi reduced its price objective on the company’s stock to $84 from $88, while keeping a “Neutral” rating, as reported by The Fly. Notably, the firm adjusted its targets in the broader medical technology group after Q4 reports. As per the analyst, the fundamentals are strong for the broader sector despite the current volatility. Citi Reduces PT on GE HealthCare Technologies (GEHC) ...

2026年3月18日，GE医疗完成对影像软件公司Intelerad的收购，交易金额23亿美元（约合人民币160亿）。 这笔并购并非单纯的产品补强，而更像是一次明确的战略信号： 影像行业的竞争核心，正在从"设备性 能"向"数据与平台能力"迁移。 在全球影像巨头中，这种转向已持续多年，而这次交易，将这一趋势进一步推向台前。 # 从卖设备到卖平台：一次典型的战略补课 此次被收购的Intelerad，本质是一家影像IT公司，核心产品包括PACS（影像存储与传输系统）、影像工作流 管理系统，以及面向放射科和心脏科的云端解决方案。 与传统影像设备厂商不同，这类公司并不直接生产CT或MRI，而是连接"设备—数据—医生"的中间层。 GE医疗给出的收购逻辑非常明确： 从业务结构看，Intelerad有两个关键特征值得注意： 这恰好补齐了GE医疗长期以来的短板——其优势在大型医院设备端，而在影像数据流通与院外场景布局上相 对薄弱。 换句话说，这不是一次横向扩张，而是一次"从硬件到平台"的纵向整合。 # 影像IT的底层逻辑：谁掌握数据，谁定义生态 从行业结构看，影像IT（尤其PACS和VNA）长期被视为"辅助系统"，但其战略价值正 ...

Core Insights - GE HealthCare Technologies Inc. (GEHC) has completed the acquisition of Intelerad for $2.3 billion, funded through cash and debt financing, enhancing its presence in high-growth clinics and ambulatory settings [1][7] - The integration aims to create a comprehensive, cloud-first, and AI-driven imaging platform, expected to reduce infrastructure costs and accelerate deployment timelines [2][3] Acquisition Details - Intelerad's technology will enhance GEHC's imaging capabilities, simplifying workflows and enabling precise care across healthcare settings [3][5] - Intelerad is projected to generate $270 million in revenues, with 90% recurring and EBITDA margins above 30% [7][9] - The acquisition aligns with GEHC's long-term vision of delivering seamless, data-driven care across the healthcare continuum [8] Financial Impact - The acquisition is expected to be immediately accretive to GEHC's revenue growth and adjusted EBIT margins, though it may slightly dilute adjusted EPS in the near term due to financing costs [10] - GEHC targets a high-single-digit return on invested capital by year five post-acquisition [10] Market Context - The AI-based medical imaging market is valued at $2.57 trillion in 2026, with a projected CAGR of 27.6% through 2035, driven by demand for accurate diagnosis and advancements in technology [12][13] - The acquisition strengthens GEHC's growth outlook by expanding its enterprise imaging footprint and enhancing its portfolio of AI and digital tools [5][9]

Key Takeaways GE HealthCare partners with Springbok to combine MRI tech with AI muscle analytics.Collaboration aims to deliver precise, quantitative insights on muscle health and recovery.Integration could expand GE HealthCare's reach in sports medicine and performance analytics.GE HealthCare Technologies Inc. (GEHC) has announced a development partnership with Springbok Analytics to combine its MRI technology with Springbok’s AI-powered analysis platform, with the goal of transforming how muscle health is ...

CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced that it has completed the acquisition of Intelerad, a leading medical imaging software provider for the healthcare industry, for a base purchase price of $2.3 billion in cash (subject to customary adjustments). Intelerad's technology and customer base will extend GE HealthCare's reach into high-growth specialized clinics and ambulatory care environments, complementing the company's strength in hospital-based imaging. These combined capabil. ...